All In Biotech

Drug Trial Radar · NCT00789750

Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 562 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

562

Actual

Start

Apr 2009

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • ColesevelamDrug

    Colesevelam 625 mg tablets

  • PlaceboDrug

    Placebo tablets appearing to be colesevelam

  • PioglitazoneDrug

    30 mg or 45 mg pioglitazone therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24Time frame: Baseline, Week 24

Locations

141 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Green Valley, Arizona

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Searcy, Arkansas

  • Site not named

    Buena Park, California

  • Site not named

    Burbank, California

  • Site not named

    Chino, California

  • Site not named

    Garden Grove, California

  • Site not named

    Huntington Park, California

  • Site not named

    La Mirada, California

  • Site not named

    Lincoln, California

  • Site not named

    Lomita, California

  • Site not named

    Los Gatos, California

  • Site not named

    Modesto, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Tustin, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Coral Gables, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Gulf Breeze, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Ormond Beach, Florida

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.